{'fraction_non_alphanumeric': 0.024132730015082957, 'fraction_numerical': 0.006033182503770739, 'mean_word_length': 5.775510204081633, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Combination therapy of pentoxifylline and TNFα monoclonal antibody in dextran sulphate‐induced mouse colitis

Tumour necrosis factor‐alpha (TNFα) has been suspected of playing an important role in the pathogenesis of inflammatory bowel diseases, and has become a target for the treatment of these diseases. Open‐label, placebo controlled studies have shown that engineered CDP571 and chimeric anti‐TNF antibody (cA2) provide a significant benefit in Crohn’s disease. Since these antibodies have to be used repeatedly to maintain remission in inflammatory bowel disease, there is a concern that their use may compromise host defence and produce toxic side‐effects.